Editorials: Controversies in Family Medicine
Should the Target A1C Level Be Less Than 7 Percent? No: The Case for Modest Glycemic Control in Patients with Type 2 Diabetes
Am Fam Physician. 2012 Dec 15;86(12):online.
Related editorial: Should the Target A1C Level Be Less Than 7 Percent? Yes: This Should Be the Target for Most Patients.
This is one in a series of pro/con editorials discussing controversial issues in family medicine.
Between firmly held beliefs in tight glycemic control and the available empiric data lies a wide chasm. In a review of 13 randomized controlled trials (RCTs) comparing tight control versus usual care in patients with type 2 diabetes mellitus, overall, tight control did not improve all-cause mortality, cardiovascular mortality, or total myocardial infarctions.1 There was a decrease in the rate of nonfatal myocardial infarctions, but between 117 and 150 patients would have to be treated for five years to prevent one myocardial event. If you omit two poor-quality studies, the benefit for any outcome disappears, except for less progression to microalbuminuria. However, only 15 to 52 patients would need to be treated per year with tight control to cause one severe episode of hypoglycemia.
Several arguments in favor of tight control come to mind, such as the need to preserve islet cells, the association between glycemic control and complications, and the use of highly selected populations in the above studies. However, none of those arguments hold up.
Early preservation of islet cell function, the world's greatest glucose monitoring and management system, is arguably the key to avoiding complications. Yet in spite of this interesting hypothesis, the outcomes of patients with screen-detected diabetes treated intensively are no different than those of patients treated with usual care.2
In a study commonly used to justify tight control, the investigators ignored the RCT data, finding no benefit to tight control, and pooled both groups to emulate a cohort study.3 They found a linear relationship between A1C levels and the rate of aggregated diabetes-related end points. However, since the RCTs found no benefit, this study raises concerns about tight control. The authors projected a 21 percent reduction in any diabetic complication and diabetes-related death, a 14 percent reduction in myocardial infarctions, and a 37 percent reduction in microvascular complications for every 1 percent decrease in A1C. However, these effects have not been shown in RCTs. Therefore, this cohort study confirms that poor glycemic control is a marker for bad outcomes—and if the conclusions are correct, the treatments are harmful.
Finally, the individual studies included a range of patients with newly diagnosed diabetes,4 patients at high risk of coronary artery disease,5,6 and patients with poorly controlled diabetes.7 Each of these trials, although evaluating heterogeneous populations, failed to demonstrate any meaningful benefit to tight glycemic control.
By balancing safety and effectiveness based on the best available evidence from recent RCTs, a stronger argument can be made for modest control with A1C goals between 7 and 8 percent. In fact, the Health-care Effectiveness Data and Information Set defines poor control as an A1C level of more than 9 percent, and suggests that most patients should have an A1C level of less than 8 percent.8
Diabetes is more complicated than merely maintaining glycemic control. We have good RCT evidence that blood pressure control, smoking cessation, attention to diet and exercise, and treatment of hyperlipidemia reduce cardiovascular or all-cause mortality in patients with type 2 diabetes.9–11 Patients with diabetes need a comprehensive approach that includes self-care, monitoring for complications and, yes, some degree of glycemic control.
Setting a one-size-fits-all standard for glycemic control is presumptuous. The wise family physician should engage in a discussion with his or her patient, incorporating all of the data, to determine treatment goals that are consistent with the patient's values and preferences.
REFERENCESshow all references
1. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169....
2. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a clusterrandomised trial [published correction appears in Lancet. 2012;379(9818):804]. Lancet. 2011;378(9786):156–167.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837–853.
5. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
6. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
7. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published corrections appear in N Engl J Med. 2009;361(10):1028, and N Engl J Med. 2009;361(10):1024–1025]. N Engl J Med. 2009;360(2):129–139.
8. National Committee for Quality Assurance. 2012 HEDIS disease management measures. http://www.ncqa.org/LinkClick.aspx?fileticket=TscF0-rEcNg%3d&tabid=1256. Accessed January 8, 2012.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444.
10. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713–720.
11. Tight blood pressure control and risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published correction appears in BMJ. 1999;318(7175):29]. BMJ. 1998;317(7160):703–713.
Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 1, 2016
Access the latest issue of American Family Physician